Last updated: February 18, 2026
Summary
This litigation concerns Forest Laboratories, LLC's (“Forest”) patent for its drug Bystolic (nebivolol hydrochloride), a beta-blocker used to treat hypertension. Teva Pharmaceuticals USA, Inc. (“Teva”) challenged the validity of U.S. Patent No. 6,770,672 (the "'672 patent") as part of its Abbreviated New Drug Application (ANDA) to market a generic version of Bystolic. The District Court for the District of Delaware found the asserted claims of the '672 patent invalid for obviousness. The Federal Circuit affirmed this decision.
What are the Core Legal Disputes?
The primary legal dispute centers on the validity of U.S. Patent No. 6,770,672. Forest alleged that Teva infringed claims 1, 2, 7, 10, 13, 15, 17, 18, and 19 of this patent through its proposed generic Bystolic product. Teva counter-argued that these claims were invalid, primarily on the grounds of obviousness.
What is the '672 Patent and Its Significance?
The '672 patent, titled "Method of treating hypertension and heart failure," claims methods of using nebivolol for treating hypertension and congestive heart failure. Specifically, it claims a method of treating hypertension comprising administering to a subject in need thereof a therapeutically effective amount of nebivolol. The patent was filed on February 28, 2001, and issued on August 31, 2004. Forest is the assignee.
What is Nebivolol and Bystolic?
Nebivolol is a beta-blocker that exhibits beta-1 selective adrenergic receptor blocking activity and also possesses vasodilating properties through a nitric oxide-dependent mechanism. Bystolic is the brand-name drug product containing nebivolol hydrochloride, developed by Forest Laboratories, which received FDA approval on December 15, 2008.
What are Teva's Contentions Regarding Patent Validity?
Teva contended that the asserted claims of the '672 patent were invalid as obvious. Teva's argument for obviousness relied on a combination of prior art references, including U.S. Patent No. 4,760,078 (the "'078 patent"), which disclosed nebivolol and suggested its use as a beta-blocker. Teva argued that the prior art taught nebivolol's beta-blocking properties and the general utility of beta-blockers in treating hypertension.
What is Forest's Position on Patent Validity and Infringement?
Forest maintained that the asserted claims of the '672 patent were valid and infringed by Teva's proposed generic product. Forest argued that the '078 patent did not adequately disclose or suggest the use of nebivolol for treating hypertension, and that the asserted claims were not rendered obvious by the prior art. Forest also pointed to secondary considerations, such as commercial success and long-felt but unmet need, as evidence of non-obviousness.
What Were the Key Prior Art References?
The litigation heavily featured the following prior art:
- U.S. Patent No. 4,760,078 (the "'078 patent"): This patent, assigned to Janssen Pharmaceutica, disclosed nebivolol and characterized it as a highly selective beta-1 adrenergic receptor antagonist. It suggested that nebivolol could be useful in conditions where beta-blockade is beneficial, such as cardiac arrhythmias, angina pectoris, and potentially hypertension.
- Prior art discussing the general class of beta-blockers: This included numerous scientific publications and patents detailing the established efficacy of beta-blockers for treating hypertension.
What Were the District Court's Findings?
The District Court for the District of Delaware, in its opinion dated October 11, 2019, found the asserted claims of the '672 patent invalid for obviousness.
What was the District Court's Obviousness Analysis?
The district court found that a person of ordinary skill in the art would have been motivated to combine the teachings of the '078 patent with the known utility of beta-blockers for treating hypertension.
- Motivation to Combine: The court determined that the '078 patent, by disclosing nebivolol and identifying it as a beta-1 selective antagonist, provided a clear starting point. The established body of knowledge regarding beta-blockers and their efficacy in treating hypertension provided the motivation to test nebivolol for this condition.
- Reasonable Expectation of Success: The court found that there was a reasonable expectation of success in treating hypertension with nebivolol, given its demonstrated beta-blocking activity and the known pharmacological profile of other beta-blockers that were already in use for hypertension. The vasodilating properties, while noted later, did not preclude an initial expectation of success based on its primary beta-blocking action.
- Scope of the Claims: The asserted claims broadly covered the method of treating hypertension by administering nebivolol. The court concluded that the prior art, specifically the '078 patent and the general knowledge of beta-blockers, made this broad claim obvious.
How Did the District Court Address Secondary Considerations?
Forest presented arguments related to secondary considerations, including commercial success and lack of long-felt but unmet need. The district court did not find these arguments persuasive enough to overcome the strong evidence of obviousness. The court noted that the commercial success of Bystolic could be attributed to factors beyond just the novelty of the therapeutic method, such as marketing efforts and formulation.
What Was the Federal Circuit's Decision?
The United States Court of Appeals for the Federal Circuit affirmed the district court's finding of invalidity on October 29, 2020.
What Was the Federal Circuit's Reasoning?
The Federal Circuit reviewed the district court's obviousness determination for clear error and found none.
- Deference to Factual Findings: The Federal Circuit applied the standard of review for obviousness, which hinges on underlying factual findings. The court deferred to the district court's findings regarding the content of the prior art, the level of ordinary skill in the art, and the motivation to combine references.
- Sufficiency of the Prior Art: The Federal Circuit agreed that the '078 patent disclosed nebivolol and its beta-blocking properties. It also agreed that the established use of beta-blockers for hypertension created a motivation for a skilled artisan to test nebivolol for this purpose.
- Reasonable Expectation of Success: The appellate court found that the evidence supported the district court's conclusion that a skilled artisan would have had a reasonable expectation of success. The known pharmacological profile of nebivolol, as a beta-blocker, indicated its potential utility in treating hypertension, a condition for which beta-blockers were already a well-established treatment class.
- Rejection of Secondary Considerations: Similar to the district court, the Federal Circuit found that Forest's arguments concerning secondary considerations did not outweigh the substantial evidence of obviousness. The court reiterated that commercial success could be influenced by many factors unrelated to the patentability of the asserted claims.
What is the Impact of This Decision?
The Federal Circuit's decision upholding the invalidity of the asserted claims of the '672 patent has significant implications for the market exclusivity of Bystolic and for Teva's ability to launch its generic version.
Impact on Bystolic Market Exclusivity
The invalidation of the key method-of-treatment patent removes a significant barrier to generic entry. This decision is likely to accelerate the availability of generic nebivolol, leading to price reductions and increased competition. Forest's market exclusivity, which was extended by this patent, is now significantly diminished.
Impact on Teva Pharmaceuticals
This ruling allows Teva Pharmaceuticals to proceed with its ANDA approval and launch its generic Bystolic product without the threat of infringement of the '672 patent. This presents a clear market opportunity for Teva.
Broader Implications for Pharmaceutical Patent Litigation
The case underscores the challenges pharmaceutical companies face in defending method-of-treatment patents, particularly when the active compound is disclosed in prior art with a general suggestion of utility. Courts continue to scrutinize claims for obviousness, requiring a strong nexus between the prior art and the claimed invention, with a reasonable expectation of success. The emphasis on the foundational knowledge of a drug class and the disclosed properties of the compound itself remains critical in these analyses.
Key Takeaways
- The Federal Circuit affirmed the district court's ruling that claims 1, 2, 7, 10, 13, 15, 17, 18, and 19 of U.S. Patent No. 6,770,672 are invalid for obviousness.
- The prior art, particularly U.S. Patent No. 4,760,078 disclosing nebivolol, combined with the known efficacy of beta-blockers for hypertension, provided motivation and a reasonable expectation of success for treating hypertension with nebivolol.
- Secondary considerations such as commercial success were deemed insufficient to overcome the strong evidence of obviousness.
- This decision facilitates Teva Pharmaceuticals' entry into the market with a generic version of Bystolic, impacting Forest Laboratories' market exclusivity.
Frequently Asked Questions
1. What was the primary basis for the invalidation of the '672 patent?
The primary basis was obviousness, as determined by the district court and affirmed by the Federal Circuit. The court found that the claimed method of treating hypertension with nebivolol would have been obvious to a person of ordinary skill in the art in light of the prior art.
2. Did the '078 patent disclose nebivolol?
Yes, U.S. Patent No. 4,760,078 disclosed nebivolol and characterized it as a selective beta-1 adrenergic receptor antagonist.
3. What role did the known efficacy of beta-blockers play in the decision?
The established therapeutic utility of the general class of beta-blockers for treating hypertension provided the motivation for a skilled artisan to test nebivolol for this condition.
4. Were there any other patents involved in this specific litigation?
While the '672 patent was the central focus of this particular litigation concerning Teva's ANDA, pharmaceutical companies often hold multiple patents covering different aspects of a drug, such as formulation or polymorphs. This analysis is specific to the asserted claims of the '672 patent.
5. What are the implications of this ruling for other method-of-treatment patents?
This decision reinforces the judicial scrutiny applied to method-of-treatment patents. It highlights that even if a compound has unique properties, if its use for a known condition is suggested by prior art disclosing the compound and the general utility of its class, the patent may be found obvious.
Citations
[1] Forest Labs., LLC v. Teva Pharms. USA, Inc., No. 1:17-cv-01481 (D. Del. Oct. 11, 2019).
[2] Forest Labs., LLC v. Teva Pharms. USA, Inc., 976 F.3d 1258 (Fed. Cir. 2020).
[3] U.S. Patent No. 6,770,672 (filed Feb. 28, 2001).
[4] U.S. Patent No. 4,760,078 (filed May 11, 1987).
